Acute Kidney Injury in Cancer Immunotherapy Recipients
Cancer immunotherapy has now entered clinical practice and has reshaped the standard of care for many cancer patients. With these new strategies, specific toxicities have emerged, and renal side effects have been described. In this review, we will describe the causes of acute kidney injury in CAR T...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/11/24/3991 |
| _version_ | 1797460936923021312 |
|---|---|
| author | Adrien Joseph Antoine Lafarge Elie Azoulay Lara Zafrani |
| author_facet | Adrien Joseph Antoine Lafarge Elie Azoulay Lara Zafrani |
| author_sort | Adrien Joseph |
| collection | DOAJ |
| description | Cancer immunotherapy has now entered clinical practice and has reshaped the standard of care for many cancer patients. With these new strategies, specific toxicities have emerged, and renal side effects have been described. In this review, we will describe the causes of acute kidney injury in CAR T cell, immune checkpoint inhibitors and other cancer immuno-therapy recipients. CAR T cell therapy and bispecific T cell engaging antibodies can lead to acute kidney injury as a consequence of cytokine release syndrome, tumor lysis syndrome, sepsis or specific CAR T cell infiltration. Immune checkpoint blockade most often results in acute tubular interstitial nephritis, but glomerular diseases have also been described. Although the pathophysiology remains mostly elusive, we will describe the mechanisms of renal damage in these contexts, its prognosis and treatment. As the place of immunotherapy in the anti-cancer armamentarium is exponentially increasing, close collaboration between nephrologists and oncologists is of utmost importance to provide the best standard of care for these patients. |
| first_indexed | 2024-03-09T17:13:16Z |
| format | Article |
| id | doaj.art-4dfbfd4c95c1425eb580e49efa0d4c43 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-09T17:13:16Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-4dfbfd4c95c1425eb580e49efa0d4c432023-11-24T13:53:58ZengMDPI AGCells2073-44092022-12-011124399110.3390/cells11243991Acute Kidney Injury in Cancer Immunotherapy RecipientsAdrien Joseph0Antoine Lafarge1Elie Azoulay2Lara Zafrani3Medical Intensive Care Unit, Saint-Louis Teaching Hospital, Public Assistance Hospitals of Paris, 75010 Paris, FranceMedical Intensive Care Unit, Saint-Louis Teaching Hospital, Public Assistance Hospitals of Paris, 75010 Paris, FranceMedical Intensive Care Unit, Saint-Louis Teaching Hospital, Public Assistance Hospitals of Paris, 75010 Paris, FranceMedical Intensive Care Unit, Saint-Louis Teaching Hospital, Public Assistance Hospitals of Paris, 75010 Paris, FranceCancer immunotherapy has now entered clinical practice and has reshaped the standard of care for many cancer patients. With these new strategies, specific toxicities have emerged, and renal side effects have been described. In this review, we will describe the causes of acute kidney injury in CAR T cell, immune checkpoint inhibitors and other cancer immuno-therapy recipients. CAR T cell therapy and bispecific T cell engaging antibodies can lead to acute kidney injury as a consequence of cytokine release syndrome, tumor lysis syndrome, sepsis or specific CAR T cell infiltration. Immune checkpoint blockade most often results in acute tubular interstitial nephritis, but glomerular diseases have also been described. Although the pathophysiology remains mostly elusive, we will describe the mechanisms of renal damage in these contexts, its prognosis and treatment. As the place of immunotherapy in the anti-cancer armamentarium is exponentially increasing, close collaboration between nephrologists and oncologists is of utmost importance to provide the best standard of care for these patients.https://www.mdpi.com/2073-4409/11/24/3991immunotherapyacute kidney injuryimmune checkpoint inhibitorschimeric antigen receptor T cell therapycancer |
| spellingShingle | Adrien Joseph Antoine Lafarge Elie Azoulay Lara Zafrani Acute Kidney Injury in Cancer Immunotherapy Recipients Cells immunotherapy acute kidney injury immune checkpoint inhibitors chimeric antigen receptor T cell therapy cancer |
| title | Acute Kidney Injury in Cancer Immunotherapy Recipients |
| title_full | Acute Kidney Injury in Cancer Immunotherapy Recipients |
| title_fullStr | Acute Kidney Injury in Cancer Immunotherapy Recipients |
| title_full_unstemmed | Acute Kidney Injury in Cancer Immunotherapy Recipients |
| title_short | Acute Kidney Injury in Cancer Immunotherapy Recipients |
| title_sort | acute kidney injury in cancer immunotherapy recipients |
| topic | immunotherapy acute kidney injury immune checkpoint inhibitors chimeric antigen receptor T cell therapy cancer |
| url | https://www.mdpi.com/2073-4409/11/24/3991 |
| work_keys_str_mv | AT adrienjoseph acutekidneyinjuryincancerimmunotherapyrecipients AT antoinelafarge acutekidneyinjuryincancerimmunotherapyrecipients AT elieazoulay acutekidneyinjuryincancerimmunotherapyrecipients AT larazafrani acutekidneyinjuryincancerimmunotherapyrecipients |